Harmony Biosciences Inc. (HRMY)
undefined
undefined%
At close: undefined
32.39
0.03%
After-hours Dec 13, 2024, 04:00 PM EST

Harmony Biosciences Statistics

Share Statistics

Harmony Biosciences has 57.03M shares outstanding. The number of shares has increased by -2.97% in one year.

Shares Outstanding 57.03M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.08%
Owned by Institutions (%) n/a
Shares Floating 40.49M
Failed to Deliver (FTD) Shares 44
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 6.06M, so 10.62% of the outstanding shares have been sold short.

Short Interest 6.06M
Short % of Shares Out 10.62%
Short % of Float 14.96%
Short Ratio (days to cover) 6.8

Valuation Ratios

The PE ratio is 14.91 and the forward PE ratio is 10.76. Harmony Biosciences 's PEG ratio is 0.14.

PE Ratio 14.91
Forward PE 10.76
PS Ratio 3.3
Forward PS 2.2
PB Ratio 4.11
P/FCF Ratio 8.77
PEG Ratio 0.14
Financial Ratio History

Enterprise Valuation

Harmony Biosciences Inc. has an Enterprise Value (EV) of 1.80B.

EV / Earnings 13.99
EV / Sales 3.1
EV / EBITDA 8.14
EV / EBIT 9.39
EV / FCF 8.23

Financial Position

The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.41.

Current Ratio 2.75
Quick Ratio 2.72
Debt / Equity 0.41
Total Debt / Capitalization 29.3
Cash Flow / Debt 1.13
Interest Coverage 8.08

Financial Efficiency

Return on equity (ROE) is 0.28% and return on capital (ROIC) is 21.6%.

Return on Equity (ROE) 0.28%
Return on Assets (ROA) 0.16%
Return on Capital (ROIC) 21.6%
Revenue Per Employee 2.37M
Profits Per Employee 523.79K
Employee Count 246
Asset Turnover 0.72
Inventory Turnover 22.61

Taxes

Income Tax 44.54M
Effective Tax Rate 0.26

Stock Price Statistics

The stock price has increased by -3.83% in the last 52 weeks. The beta is 0.77, so Harmony Biosciences 's price volatility has been higher than the market average.

Beta 0.77
52-Week Price Change -3.83%
50-Day Moving Average 34.34
200-Day Moving Average 33.02
Relative Strength Index (RSI) 38.49
Average Volume (20 Days) 762.76K

Income Statement

In the last 12 months, Harmony Biosciences had revenue of $582.02M and earned $128.85M in profits. Earnings per share was $2.17.

Revenue 582.02M
Gross Profit 460.79M
Operating Income 192.03M
Net Income 128.85M
EBITDA 221.51M
EBIT 192.03M
Earnings Per Share (EPS) 2.17
Full Income Statement

Balance Sheet

The company has $311.66M in cash and $193.57M in debt, giving a net cash position of $118.09M.

Cash & Cash Equivalents 311.66M
Total Debt 193.57M
Net Cash 118.09M
Retained Earnings -143.28M
Total Assets 928.13M
Working Capital 361.13M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $219.39M and capital expenditures -$312.00K, giving a free cash flow of $219.07M.

Operating Cash Flow 219.39M
Capital Expenditures -312.00K
Free Cash Flow 219.07M
FCF Per Share 3.68
Full Cash Flow Statement

Margins

Gross margin is 79.17%, with operating and profit margins of 32.99% and 22.14%.

Gross Margin 79.17%
Operating Margin 32.99%
Pretax Margin 29.79%
Profit Margin 22.14%
EBITDA Margin 38.06%
EBIT Margin 32.99%
FCF Margin 37.64%

Dividends & Yields

HRMY does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 6.7%
FCF Yield 11.86%
Dividend Details

Analyst Forecast

The average price target for HRMY is $52, which is 60.6% higher than the current price. The consensus rating is "Buy".

Price Target $52
Price Target Difference 60.6%
Analyst Consensus Buy
Analyst Count 9
Stock Forecasts

Scores

Altman Z-Score 5.06
Piotroski F-Score 7